ストックスクリーナーアプリを入手
0.2701
9.50%
-0.0279
Gri Bio Inc (GRI) 最新ニュース
GRI Bio stock rises on positive Phase 2a immune data for IPF treatment - Investing.com
GRI Bio reports positive Phase 2a data for IPF treatment By Investing.com - Investing.com India
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
Experimental drug shows signs of reversing lung scarring in IPF study - Stock Titan
What Wall Street predicts for GRI Bio Inc. stock priceBullish Engulfing Patterns & Small Entry Portfolio - ulpravda.ru
What technical signals suggest for GRI Bio Inc. stock2026 world cup usa national team third place match goalkeepers high defensive line group prediction insights - ulpravda.ru
What drives GRI Bio Inc stock priceEarnings Forecast Updates & High Yield Trading Growth - earlytimes.in
Decliners Report: Is GRI Bio Inc stock attractive for hedge funds2025 Bull vs Bear & Free Community Consensus Stock Picks - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about GRI Bio Inc. stockLong Setup & Real-Time Buy Zone Alerts - Улправда
Why GRI Bio Inc. stock remains on buy listsWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Why GRI Bio Inc. stock could be next big winnerJuly 2025 Intraday Action & Expert Approved Momentum Ideas - DonanımHaber
What sentiment indicators say about GRI Bio Inc. stockWeekly Market Outlook & Weekly Momentum Stock Picks - Улправда
Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data - Pulmonary Fibrosis News
GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints - MSN
GRI Bio Closes $8 Million Public Offering - The Globe and Mail
GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Nigeria
GRI Bio closes $8 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio Launches $6.7 Million Public Offering - TipRanks
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com
GRI Bio announces pricing of $8M public offering - MSN
GRI Bio’s IPF drug shows positive Phase 2a results with improved lung function - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
GRI Bio Announces Pricing of $8,000,000 Million Public Offering - The Manila Times
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
What's Going On With GRI Bio Stock Thursday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s tazarotene achieves Phase IIa IPF success - Yahoo
GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis - Nasdaq
GRI Bio announces positive Phase 2a trial results - MSN
GRI Bio Announces Positive Phase 2a Trial Results - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - Setenews
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Financial Contrast: CalciMedica (NASDAQ:CALC) and GRI Bio (NASDAQ:GRI) - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a Trial Results - TipRanks
GRI Bio Increceives topline data from phase 2a trial for idiopathic pulmonary fibrosisSEC filing - marketscreener.com
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
Ascendiant Capital Maintains GRI Bio (GRI) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for GRI to $36.00 | GRI S - GuruFocus
Why GRI Bio Inc. stock is seen as undervaluedSell Signal & Weekly Return Optimization Alerts - Newser
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - The Herald-Mail
GRI Bio receives Nasdaq notice for non-compliance with equity listing rule - Investing.com Australia
5.77%
大文字化:
|
ボリューム (24 時間):